1、ANNUAL REPORTFiscal year ending March 3140M+pharmaceutical and medical supply deliveries annuallyStrength in Distribution99%pharmaceutical order accuracy in North America285,000+customers served with medical-surgical productsSuperior Specialty Assets1.4+million patients annually treated by The US On

2、cology Network physicians+1,000 clinical trials actively enrollingLeading distributor in oncology and specialty therapiesTechnology DifferentiationConnected to payers representing 94%of U.S.prescription volumeAccess to research data from 2.4M patient records including 85 oncology indicationsBiopharm

3、a ServicesMore than 650 biopharma brands servedIncreased value to biopharma and enabled$8.8B in prescription savings95%of therapeutic areasSupportedNetwork of 950,000 providers and over 50,000 pharmaciesAt McKesson,we are about Advancing Health Outcomes for All To our valued shareholders:?McKesson S

4、trategy?1|Focus on People and Culture?the future of health starts with you?2|Drive Sustainable Core Growth?3|Expand Oncology and Biopharma Platforms?4|Evolve and Grow the Portfolio?Advancing Health Outcomes for All?Brian Tyler?UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549FORM 1

5、0-KANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended March 31,2024ORTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period fromtoCommission File Number:1-13252McKESSON CORPORATION(Exa

6、ct name of registrant as specified in its charter)Delaware94-3207296(State or other jurisdiction of incorporation or organization)(I.R.S.Employer Identification No.)6555 State Hwy 161,Irving,TX 75039(Address of principal executive offices,including zip code)(972)446-4800(Registrants telephone number